Surgery Partners Posts $21.1M Q3 Loss as $25.00 HealthSpan Deal Terms Detailed
SGRY has more than doubled off its 52-week low of $11.41 on elevated volume (4.4× avg).
Summary
Surgery Partners reported a $21.1M Q3 net loss on $815.3M of revenue and disclosed full terms of its amended $25.00-per-share HealthSpan merger, including a ticking fee of up to $1.61 per share and a $149.1M termination fee.
Key Events · Earnings and Guidance · SGRY
-
Q3 Revenue Slips, Loss Widens
Revenue fell 0.8% to $815.3M from $821.5M, and net loss attributable to Surgery Partners was $21.1M (-$0.16 per diluted share) versus $22.7M a year earlier.
-
Adjusted EBITDA Down 2.7%
Adjusted EBITDA was $132.7M versus $136.4M, while same-facility days-adjusted revenue grew 6.0% on a 5.8% increase in revenue per case.
-
Merger Terms Fully Detailed
The amended HealthSpan deal pays $25.00 per share in cash, adds a 10% annual ticking fee capped at $1.61 per share, carries a $149.1M termination fee and an $8.25M expense reimbursement cap, with an outside date of October 23, 2027.
-
Idaho Sale Closed, Debt Paid Down
The $796.6M Idaho Transaction closed September 14, 2026, producing a $12.5M pre-tax gain net of $23.4M in fees; the company also made a $285.0M voluntary term loan prepayment.
Analysis · SGRY · Industrial Applications And Services
The quarter itself is soft: revenue slipped 0.8% to $815.3M and Adjusted EBITDA fell 2.7% to $132.7M, with the Idaho hospital sale removing revenue and a payor mix shift toward lower-paying government plans (47.7% of patient revenue vs 43.5% a year ago). But the stock now trades on the merger, not the quarter. For the first time in a periodic report, the 10-Q lays out the full amended HealthSpan terms: $25.00 per share in cash, a 10% annual ticking fee worth up to $1.61 per share if the deal slips past March 1, 2027, a $149.1M termination fee, and an outside date of October 23, 2027. With $354.5M of cash and $692.8M of revolver capacity after a $285.0M debt prepayment, the balance sheet is not the issue — closing the deal is.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGRY was trading at $26.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $11.41 to $27.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.